Heart Attack Cell Therapy Shows Positive Results

1 August 2010 (Last Updated August 1st, 2010 18:30)

Heart attack cell therapy MultiStem is well tolerated when administered to damaged regions of the heart following acute myocardial infarction, according to the results of a Phase I clinical trial. Angiotech Pharmaceuticals and their partner, Athersys, said the allogeneic cell therapy

Heart attack cell therapy MultiStem is well tolerated when administered to damaged regions of the heart following acute myocardial infarction, according to the results of a Phase I clinical trial.

Angiotech Pharmaceuticals and their partner, Athersys, said the allogeneic cell therapy product also had meaningful impact on improving heart function in treated patients following a heart attack.

The dose escalation study assessed the safety and maximum tolerated dose of a single administration of MultiStem administered to acute myocardial infarction patients.

The primary endpoints were the evaluation acute adverse events during the first 24 hours following administration, post-acute adverse events up to 30 days later, and catheter-related events.

The study found no clinically significant changes to vital signs, allergic reactions, infusion-related toxicities or clinically significant cardiac adverse events associated with MultiStem administration.

All three dose groups in the study showed improvement in mean left ventricular ejection fraction (LVEF), a measure of heart function, compared to baseline and relative to the registry group.

Among patients with more severe heart attacks, two dose groups each showed better than 25% improvement in mean LVEF over baseline at four months post-treatment.